<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743065</url>
  </required_header>
  <id_info>
    <org_study_id>HEPA-China-002</org_study_id>
    <nct_id>NCT02743065</nct_id>
  </id_info>
  <brief_title>HepaSphere Chemoembolization in Advanced HCC Patients: Safety &amp; Efficacy Registry in China</brief_title>
  <acronym>SUPER-China</acronym>
  <official_title>Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety &amp; Efficacy Registry in China (SUPER-China)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fifth Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter registry is to gather the safety, efficacy and survival data
      in advanced HCC patients treated with HepaSphere in China in order to evaluate the
      application of HepaSphere deTACE in treating advanced HCC patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2- years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress-free-survival (PFS)</measure>
    <time_frame>2-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Device: HepaSphere Microspheres</arm_group_label>
    <description>HepaSphere Microsphere</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HepaSphere with 50-75mg Doxorubicin</intervention_name>
    <description>HepaSphere with 50-75mg Doxorubicin</description>
    <arm_group_label>Device: HepaSphere Microspheres</arm_group_label>
    <other_name>Superaborbent Polymer Microsphere</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Advanced Hepatocellular Carcinoma (HCC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older

          2. Patient has signed informed consent

          3. Patient must have a diagnosis of hepatocellular cancer by at least one of the
             following method:

               1. Histological confirmation

               2. Classic imaging characteristics of HCC: Early enhancement (Arterial
                  hypervascularity) and Venous or Delayed phase washout in multidetector contrast
                  enhanced computed tomography (CT) scan / dynamic contrast-enhanced magnetic
                  resonance imaging (MRI) imaging.

                    -  Either CT/ MRI shows at least one solid liver lesion ≥ 2 cm with the above
                       described imaging characteristics of HCC.

                    -  In case of liver lesion between 1 and 2 cm, both CT and MRI imaging have to
                       be performed in order to confirm the imaging characteristics of HCC.

          4. At time of study entry.

               1. Patients not suitable for ablation due to lesion location may be enrolled

               2. Patients with HCC recurrence but not suitable for resection or ablation maybe
                  enrolled

          5. Patient MUST be with BCLC stage C and meet the following criteria:

               -  Stage Child-Pugh A or B AND

               -  Performance status ECOG ≤ 2 WITH Vascular Invasion or WITHOUT Vascular invasion

          6. Patient has a life expectancy of at least 6 months

        Exclusion Criteria:

          1. Current or previous treatment with chemo- or radiation therapy or sorafenib

          2. Previous treatment of transarterial chemoembolization (TACE)

          3. Patients with current or history of any other cancer except non-melanomatous skin
             cancer

          4. Female patients who are pregnant, breastfeeding, or premenopausal and not using an
             effective method of contraceptive

          5. Performance status ECOG &gt; 2

          6. Child-Pugh Class C

          7. Occlusive tumor thrombus to the main portal trunk

          8. Active gastrointestinal bleeding

          9. Evidence of uncorrectable bleeding diathesis

         10. Extra-Hepatic spread of the HCC

         11. &gt;50% tumor involvement of the liver

         12. Infiltrative HCC

         13. Encephalopathy not adequately controlled medically

         14. Presence of ascites not controlled medically

         15. Any contraindication for MRI/ CT (eg. metallic implants)

         16. Allergy to contrast media that cannot be managed with prophylaxis

         17. Any contraindication to arteriography

         18. Any contraindication for doxorubicin administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Shan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fifth Affiliated Hospiatl, Sun Yet-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingsheng Huang, MD</last_name>
    <phone>+86 020 85252066</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junwei Chen</last_name>
    <phone>+86 020 85252066</phone>
    <email>aaronchan83@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huai Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fifth Affiliated Hospiatl, Sun Yet-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Shan, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Long Fei Peng, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaofeng He, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospiatl, Sun Yet-Sen Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingsheng Huang, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Junwei Chen, MD</last_name>
      <phone>+86 020 85252066</phone>
      <email>aaronchan83@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yefa Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiping Yan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuhai People's Hospital</name>
      <address>
        <city>Zhuhai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ligong Lu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fifth Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Hong Shan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HepaSphere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

